Roy Meland, DO
Psychiatry · Lansing, MINPI 1376500330
Payments from drug & device makers
Across 477 payments — averaging $15.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sunovion Pharmaceuticals Inc.$1K
- Johnson & Johnson$723
- AbbVie$645
- Lundbeck LLC$628
- Otsuka America Pharmaceutical, Inc.$607
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$572
- plus $3K from 22 others
What the payments were for
- Consulting fees$2003%
- Food & beverage$7,04095%
- Education$1782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sunovion Pharmaceuticals Inc. | 99 | $1,294 |
| Johnson & Johnson | 40 | $723 |
| AbbVie(2 entities) | 57 | $645 |
| Lundbeck LLC | 40 | $628 |
| Otsuka America Pharmaceutical, Inc. | 41 | $607 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 35 | $572 |
| Neurocrine Biosciences, Inc. | 30 | $509 |
| Vanda Pharmaceuticals Inc. | 16 | $382 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $298 |
| Jazz Pharmaceuticals Inc. | 15 | $241 |
| Teva Pharmaceuticals USA, Inc. | 15 | $229 |
| Janssen Scientific Affairs, LLC | 1 | $200 |
| Alkermes, Inc. | 9 | $181 |
| Ironshore Pharmaceuticals Inc. | 12 | $175 |
| Neuronetics, Inc. | 7 | $168 |
| Neos Therapeutics, LP | 9 | $125 |
| Eisai Inc. | 9 | $121 |
| Shire North American Group Inc | 10 | $112 |
| Acadia Pharmaceuticals Inc | 4 | $67 |
| Livanova USA, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Harmony Biosciences LLC | 1 | $20 |
| Corium, LLC | 1 | $17 |
| Novartis | 1 | $15 |
| Indivior Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Merck | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPRAVATO$311
How this compares
$7,418 in reported general payments places this provider in the 90th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 56 | $86,172 |
| RexultiBrexpiprazole | 29 | $54,972 |
| TrintellixVortioxetine Hydrobromide | 70 | $50,709 |
| SpravatoEsketamine Hcl | 43 | $49,655 |
| EmsamSelegiline | 24 | $49,560 |
| LatudaLurasidone Hcl | 11 | $16,574 |
| VyvanseLisdexamfetamine Dimesylate | 38 | $16,550 |
| Lisdexamfetamine Dimesylate | 58 | $15,552 |
| SunosiSolriamfetol Hcl | 12 | $15,240 |
| BelsomraSuvorexant | 22 | $14,956 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 141 | $13,278 |
| Lurasidone Hcl | 48 | $12,691 |
| NamzaricMemantine Hcl/Donepezil Hcl | 12 | $10,261 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 117 | $6,641 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 214 | $5,767 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Namzaric | $645 | $96,43468 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $298 | $67,259108 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $607 | $54,97229 claims |
| Johnson & JohnsonSpravato | $723 | $49,65543 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $1,294 | $16,57411 claims |
| MerckBelsomra | $12 | $14,95622 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $175 | $5,67612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Lansing
- John BakerLansing$20K
- Dale DmelloLansing$11K
- Andreas SidiropoulasDetroit$2.8M
- Joel YoungRochester Hills$1.9M
- Welton WashingtonYpsilanti$1.4M
- Rajaprabhakaran RajarethinamAnn Arbor$1.2M
- Eric AchtyesGrand Rapids$705K
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Brian MickeyAnn Arbor$490K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.